| Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2–positive breast cancer J Shou, S Massarweh, CK Osborne, AE Wakeling, S Ali, H Weiss, R Schiff Journal of the National Cancer Institute 96 (12), 926-935, 2004 | 1515 | 2004 |
| Mechanisms of endocrine resistance in breast cancer CK Osborne, R Schiff Annual review of medicine 62, 233-247, 2011 | 1377 | 2011 |
| Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer CK Osborne, V Bardou, TA Hopp, GC Chamness, SG Hilsenbeck, ... Journal of the National Cancer Institute 95 (5), 353-361, 2003 | 1059 | 2003 |
| Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes RM Lavinsky, K Jepsen, T Heinzel, J Torchia, TM Mullen, R Schiff, ... Proceedings of the National Academy of Sciences 95 (6), 2920-2925, 1998 | 891 | 1998 |
| HER2: biology, detection, and clinical implications C Gutierrez, R Schiff Archives of pathology & laboratory medicine 135 (1), 55-62, 2011 | 730 | 2011 |
| The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo KL Meerbrey, G Hu, JD Kessler, K Roarty, MZ Li, JE Fang, JI Herschkowitz, ... Proceedings of the National Academy of Sciences 108 (9), 3665-3670, 2011 | 711 | 2011 |
| Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance G Arpino, L Wiechmann, CK Osborne, R Schiff Endocrine reviews 29 (2), 217-233, 2008 | 658 | 2008 |
| Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy X Cui, R Schiff, G Arpino, CK Osborne, AV Lee Journal of clinical oncology 23 (30), 7721-7735, 2005 | 638 | 2005 |
| Estrogen receptor–positive, progesterone receptor–negative breast cancer: association with growth factor receptor expression and tamoxifen resistance G Arpino, H Weiss, AV Lee, R Schiff, S De Placido, CK Osborne, ... Journal of the National Cancer Institute 97 (17), 1254-1261, 2005 | 637 | 2005 |
| ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer R Jeselsohn, G Buchwalter, C De Angelis, M Brown, R Schiff Nature reviews Clinical oncology 12 (10), 573-583, 2015 | 611 | 2015 |
| Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase MC Gutierrez, S Detre, S Johnston, SK Mohsin, J Shou, DC Allred, ... Journal of clinical oncology 23 (11), 2469-2476, 2005 | 606 | 2005 |
| Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function S Massarweh, CK Osborne, CJ Creighton, L Qin, A Tsimelzon, S Huang, ... Cancer research 68 (3), 826-833, 2008 | 596 | 2008 |
| Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer CK Osborne, J Shou, S Massarweh, R Schiff Clinical cancer research 11 (2), 865s-870s, 2005 | 583 | 2005 |
| Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance R Schiff, SA Massarweh, J Shou, L Bharwani, SK Mohsin, CK Osborne Clinical Cancer Research 10 (1), 331s-336s, 2004 | 568 | 2004 |
| A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models X Zhang, S Claerhout, A Prat, LE Dobrolecki, I Petrovic, Q Lai, MD Landis, ... Cancer research 73 (15), 4885-4897, 2013 | 507 | 2013 |
| Estrogen-receptor biology: continuing progress and therapeutic implications CK Osborne, R Schiff Journal of Clinical Oncology 23 (8), 1616-1622, 2005 | 464 | 2005 |
| Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response R Schiff, S Massarweh, J Shou, CK Osborne Clinical Cancer Research 9 (1), 447s-454s, 2003 | 460 | 2003 |
| A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis JD Kessler, KT Kahle, T Sun, KL Meerbrey, MR Schlabach, EM Schmitt, ... Science 335 (6066), 348-353, 2012 | 459 | 2012 |
| MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis A Terunuma, N Putluri, P Mishra, EA Mathé, TH Dorsey, M Yi, TA Wallace, ... The Journal of clinical investigation 124 (1), 398-412, 2014 | 421 | 2014 |
| Au nanomatryoshkas as efficient near-infrared photothermal transducers for cancer treatment: benchmarking against nanoshells C Ayala-Orozco, C Urban, MW Knight, AS Urban, O Neumann, ... ACS nano 8 (6), 6372-6381, 2014 | 394 | 2014 |
